The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis.

摘要: // De-Dong Cao 1 , Hui-Lin Xu 2 Xi-Ming and Wei Ge Department of Oncology, RenMin Hospital Wuhan University, Wuhan, China The Fifth Correspondence to: Ge, email: gewei514@126.com Xu, doctorxu120@aliyun.com Keywords: primary tumor location, cetuximab, colorectal cancer, Kras, meta-analysis Received: August 10, 2016      Accepted: June 20, 2017      Published: July 05, 2017 ABSTRACT Objective: To assess the prognostic role location along with Kras status in metastatic cancer (mCRCs) treated cetuximab. Materials Methods: Databases EMBASE, Pubmed, Cochrane library, National Knowledge Infrastructure other databases from inception to 2016 were searched. Randomized controlled trial (RCT) and/or retrospective studies influence on efficacy cetuximab patients mCRC identified. endpoint was progression-free survival (PFS), secondary endpoints overall (OS), response rate (ORR) disease control (DCR). Results: Ten including 2977 cases finally included. results favor left-sided terms OS (HR = 0.52, 95% CI: 0.40–0.66; p < 0.01), PFS 0.64, 0.58–0.70; ORR (OR 2.17, 1.57–2.99; 0.01). Patients right-sided CRC gained less benefit 1.89, 1.43–2.50; compared CRC. Regarding status, wild type had better 0.61, 0.51–0.74; 0.01) 0.49, 0.35–0.69; than when We also found that both significantly effective different treatment lines regions comparing by locations ( Conclusions: left-sided, have a prognosis those diseases clinical application should be determined molecular gene mutation status.